Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
29 studies found for:    GIST | Open Studies | United States
Show Display Options
Rank Status Study
1 Recruiting A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: sunitinib malate dose escalation;   Drug: sunitinib malate
2 Recruiting Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor
Condition: Gastrointestinal Stromal Tumor
Intervention: Drug: AUY922
3 Unknown  A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Condition: Gastrointestinal Stromal Tumors
Interventions: Drug: masitinib (AB1010);   Drug: imatinib
4 Recruiting BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Advanced Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: BGJ398;   Drug: Imatinib Mesylate
5 Recruiting A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients
Condition: 3rd Line GIST
Intervention: Drug: ST571 + BYL719
6 Recruiting Registry Trial for Clinical Evaluation of nCLE in Masses and Cystic Tumors of the Pancreas, Lymph Nodes, Submucosal Lesions of the GI Tract
Conditions: Pancreatic Cyst;   Pancreatic Neoplasms;   Pancreatic Adenoma;   Pancreatic Cancer;   Pancreatic Islet Cell Tumors;   Lymph Node;   Lymphadenopathy;   GIST
Intervention: Device: EUS-FNA: Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
7 Recruiting Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Condition: GIST and CML
Intervention: Drug: STI571
8 Recruiting Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Conditions: Solid Tumors;   Triple-Negative Breast Cancer;   Non Small Cell Lung Cancer;   Renal Cell Carcinoma;   Mesothelioma;   Fumarate Hydratase (FH)-Deficient Tumors;   Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST);   Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors;   Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations
Intervention: Drug: CB-839
9 Recruiting Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Condition: GIST and CML
Intervention: Drug: AMN107
10 Recruiting Treatment of Social Competence After Traumatic Brain Injury
Condition: Traumatic Brain Injury
Interventions: Behavioral: Group Interactive Structured Treatment;   Behavioral: Alternative Intervention
11 Recruiting Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Condition: GIST
Intervention: Drug: Vandetanib
12 Recruiting Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
Condition: Tumor Pathway Activations Inhibited by Dovitinib
Intervention: Drug: Dovitinib (TKI258)
13 Recruiting Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: Sunitinib;   Drug: Regorafenib
14 Recruiting MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: MEK162;   Drug: Imatinib Mesylate (Gleevec®; STI571; NSC #716051)
15 Recruiting Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Conditions: Gastrointestinal Stromal Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: dasatinib;   Biological: ipilimumab;   Other: laboratory biomarker analysis;   Other: pharmacological study
16 Recruiting Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy
Condition: Gastric Cancers
Intervention:
17 Recruiting A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas
Conditions: Liposarcoma;   Osteogenic Sarcoma;   Ewing/Ewing-like Sarcoma
Interventions: Drug: Regorafenib;   Drug: Placebo
18 Unknown  Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Conditions: Stomach Cancer;   Gastric (Stomach) Cancer;   Neoplasm of Cardioesophageal Junction;   Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: bevacizumab;   Drug: carboplatin;   Drug: capecitabine
19 Recruiting Permission to Collect Blood Over Time for Research
Conditions: Pancreatic Cancer;   Gastrointestinal Neoplasms;   Colon Rectal Cancer Adenocarcinoma;   Esophageal Cancer;   Gall Bladder Cancer;   Gastric (Stomach) Cancer;   Gastrooesophageal Cancer;   Gastrointestinal Stromal Tumor (GIST);   Hepatobiliary Neoplasm;   Liver Carcinoma;   Gallbladder Carcinoma;   Bile Duct Carcinoma;   Carcinoma of the Large Intestine;   Anal Cancer
Intervention: Procedure: Observation
20 Recruiting Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
Conditions: Stomach Cancer;   Gastro-Esophageal(GE) Junction Cancer;   Gastric (Stomach) Cancer;   Esophageal Cancer;   Gastrointestinal Stromal Tumor (GIST)
Interventions: Procedure: Blood draw;   Procedure: Tissue tumor biopsy

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Indicates status has not been verified in more than two years